Document Detail


A low serum iron level is a predictor of poor outcome in hemodialysis patients.
MedLine Citation:
PMID:  15042544     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Iron administration has been implicated as a cause of poor clinical outcome in maintenance hemodialysis (MHD) patients. However, the role of low iron levels in the clinical outcome of MHD patients is not clear.
METHODS: We examined the predicting value of baseline serum iron level on prospective mortality and hospitalization in a cohort of all 1,283 MHD patients from 10 DaVita dialysis facilities in Los Angeles County, CA.
RESULTS: Patients aged 57.8 +/- 15.2 years included 49% men, 45% Hispanics, 25% African Americans, and 53% patients with diabetes. During the first 3 months of the cohort, 97% of patients were administered erythropoietin (EPO) and 60% were administered intravenous iron (gluconate and/or dextran) at least once. During a 12-month follow-up, mortality was significantly greater (23%) in the lowest serum iron quartile (<45.3 microg/dL [<8.1 micromol/L]) compared with other quartiles (10% to 12%). Multivariate Poisson and Cox models adjusted for demographic features, dialysis dose and vintage, serum albumin and ferritin and blood hemoglobin concentrations, and administered EPO and iron doses showed that both serum iron level and iron saturation ratio had significant, but inverse, associations with prospective mortality and hospitalization. There was a statistically significant trend toward greater rates of mortality and hospitalization with lower serum iron levels. This reverse association remained significant in a subcohort of 322 MHD patients after additional adjustments for comorbid conditions and serum C-reactive protein level to reflect inflammation.
CONCLUSION: Low baseline serum iron indicators are associated with increased mortality and hospitalization in MHD patients independent of hemoglobin level, EPO and iron doses, indicators of nutrition and inflammation, and comorbid conditions. Clinical trials to examine the role of iron administration in improving morbidity and mortality by increasing serum iron levels in MHD patients are required.
Authors:
Kamyar Kalantar-Zadeh; Charles J McAllister; Robert S Lehn; Enwu Liu; Joel D Kopple
Related Documents :
12771534 - Vitamin c in chronic kidney disease and hemodialysis patients.
9794284 - T2 relaxation time study of iron overload in b-thalassemia.
1955004 - S-erythropoietin levels decrease in patients with chronic hypoxia starting domiciliary ...
17704954 - Intravenous iron treatment in paediatric chronic kidney disease patients not on erythro...
21704794 - Urologic dysfunction and neurologic outcome in coma survivors after severe traumatic br...
1982784 - Bacterial peritonitis and beta-2 microglobulin (b2m) production by peritoneal macrophag...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  43     ISSN:  1523-6838     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-03-25     Completed Date:  2004-06-16     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  671-84     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Erythropoietin / therapeutic use
Female
Hospitalization
Humans
Iron / blood*,  therapeutic use
Kidney Failure, Chronic / blood,  mortality*,  therapy*
Male
Middle Aged
Poisson Distribution
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Recombinant Proteins
Renal Dialysis*
Survival Analysis
Grant Support
ID/Acronym/Agency:
DK61162/DK/NIDDK NIH HHS; K23 DK061162/DK/NIDDK NIH HHS; K23 DK061162-01/DK/NIDDK NIH HHS; K23 DK061162-02/DK/NIDDK NIH HHS; M01-RR00425/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin; E1UOL152H7/Iron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD a...
Next Document:  Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes a...